# Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas

> **NCT03172936** · PHASE1 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 106 (actual)

## Conditions studied

- Solid Tumors and Lymphomas

## Interventions

- **DRUG:** MIW815
- **BIOLOGICAL:** PDR001

## Key facts

- **NCT ID:** NCT03172936
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-09-08
- **Primary completion:** 2020-12-18
- **Final completion:** 2020-12-18
- **Target enrollment:** 106 (ACTUAL)
- **Why stopped:** Sponsor's decision
- **Last updated:** 2022-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03172936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03172936, "Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03172936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*